The Roles of STAT3 and STAT5 in Breast Cancer
Open Access
Abstract
STAT3 and STAT5 are two related transcription factors involved in normal mammary gland development and function. However, inappropriate activation of either STAT3 or STAT5 has been shown to play a role in breast cancer, where STAT3 is highly associated with aggressive tumors and STAT5 is associated with lower-grade and more differentiated tumors. As transcription factors, STAT3 and STAT5 transcriptionally regulate genes involved in proliferation, migration, and chemoresistance. Furthermore, STAT3 and STAT5 transcriptional activity can be modulated by several known cofactors, where these cofactors can influence how STAT3 and STAT5 interact with DNA and with other proteins, ultimately affecting transcriptional function. Interestingly, STAT3 and STAT5 share a subset of overlapping target genes and can compete for DNA binding of shared binding sites. These STATs have also been shown to have opposing effects on overlapping target gene expression, where gene expression is determined by the STAT protein occupying the promoter. This is particularly interesting since STAT5-driven breast tumors are molecularly distinct from STAT3-driven breast tumors. Furthermore, concurrent activation of STAT3 and STAT5 is associated with more favorable tumor types compared to tumors with activated STAT3 alone, suggesting that the relationship between these two STATs is critical. Developing a better understanding about the roles that STAT3 and STAT5 play in breast cancer will be important for successful treatment in the future.Keywords
Funding Information
- National Institute of General Medical Sciences of the National Institutes of Health (P20GM113131)
This publication has 93 references indexed in Scilit:
- METTL3-STAT5B interaction facilitates the co-transcriptional m6A modification of mRNA to promote breast tumorigenesisCancer Letters, 2024
- Prolactin receptor expression as a novel prognostic biomarker for triple negative breast cancer patientsAnnals of Diagnostic Pathology, 2020
- A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammationBreast Cancer Research and Treatment, 2018
- Molecular classification of breast cancerVirchows Archiv, 2014
- The miR‐17/92 cluster is targeted by STAT5 but dispensable for mammary developmentGenesis, 2012
- Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post‐lactational regressionThe Journal of Pathology, 2011
- Jak2/Stat5 Signaling in Mammogenesis, Breast Cancer Initiation and ProgressionJournal of Mammary Gland Biology and Neoplasia, 2008
- Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell lineCancer Letters, 2007
- The Biological Functions of the Versatile Transcription Factors STAT3 and STAT5 and New Strategies for their Targeted InhibitionJournal of Mammary Gland Biology and Neoplasia, 2006
- Leukemia Inhibitory Factor Induces Apoptosis of the Mammary Epithelial Cells and Participates in Mouse Mammary Gland InvolutionExperimental Cell Research, 2003